<DOC>
	<DOCNO>NCT00003174</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase I trial study side effect best dose cladribine give bryostatin 1 treat patient relapse chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Bryostatin 1 Plus Cladribine Treating Patients With Relapsed Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose cladribine administer bryostatin 1 patient relapse chronic lymphocytic leukemia . - Determine qualitative quantitative toxic effect regimen patient . OUTLINE : This multicenter , dose-escalation study cladribine . Patients receive bryostatin 1 IV continuously day 1-3 immediately follow cladribine IV continuously day 4-8 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Patients achieve complete remission ( CR ) receive 2 additional course past CR . Cohorts 3-6 patient receive escalate dose level cladribine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow 3 week . PROJECTED ACCRUAL : A minimum 15 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis relapse chronic lymphocytic leukemia Intermediate highrisk ( stage IIV ) disease Intermediaterisk patient must active disease , define least 1 follow criterion : Presence 1 follow diseaserelated B symptom : 10 % loss body weight within past 6 month Extreme fatigue Fever great 100 degree Fahrenheit without evidence infection Night sweat Massive ( great 6 cm leave costal margin ) progressive splenomegaly Massive ( great 10 cm long diameter ) progressive lymphadenopathy Progressive lymphocytosis increase 50 % 2month period anticipate doubling time le 12 month Progressive bone marrow failure manifest development worsen anemia and/or thrombocytopenia Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid Failed 12 prior frontline regimen Failed prior fludarabine Ineligible know treatment higher potential efficacy PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : At least 12 week Hematopoietic : See Disease Characteristics Absolute neutrophil count least 1,000/mm^3 Platelet count least 50,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL Transaminases le 2.5 time normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : No history severe coronary artery disease , cardiomyopathy , uncontrolled congestive heart failure , arrhythmias Neurologic : No prior drugrelated neurotoxicity No neurologic disorder Other : Not pregnant nursing Fertile patient must use effective barrier nonhormonal contraception 2 month study participation No HIV infection No AIDS PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow transplantation Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 8 week mitomycin nitrosoureas ) recover Endocrine therapy : See Disease Characteristics No concurrent steroids No concurrent hormonal contraceptive Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : Not specify Other : No concurrent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>